相关临床试验
320
28 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1991
进行中（未招募）
19
5.9%
已完成
170
53.1%
尚未招募
9
2.8%
招募中
37
11.6%
终止
65
20.3%
撤回
20
6.3%
暂无批准数据
- A new study in Nature Immunology challenges the decades-old paradigm that MHC class I exclusively mediates CD8+ T cell responses, revealing a previously unrecognized role in CD4+ T cell immunity. - Researchers found that when cancer cells downregulate MHC I to evade killer T cells, they paradoxically become more susceptible to CD4+ helper T cell-mediated destruction via ferroptosis. - The findings, validated in both mouse models and human clinical datasets from checkpoint inhibitor-treated patients, show correlations between this mechanism and patient outcomes. - The discovery may enable novel immunotherapies that target MHC class I and CD4+ T cells, with potential applications beyond oncology including graft-versus-host disease and autoimmune conditions.
- Genprex's Reqorsa gene therapy demonstrated a 79% tumor reduction in ALK-positive non-small cell lung cancer models during preclinical studies presented at the 2025 AACR-NCI-EROTC Conference. - The combination of Reqorsa with alectinib improved treatment outcomes by 23% compared to alectinib alone, suggesting potential as a companion therapy for advanced disease. - The positive preclinical data supports the advancement of Reqorsa toward clinical trials for ALK-EML4 positive NSCLC, a subset that primarily affects young, non-smoking individuals. - Laboratory studies show that Reqorsa's TUSC2 gene uptake in tumor cells was 10 to 33 times higher than in normal cells, demonstrating selective cancer cell targeting.
